ROC analysis using the shared genes within the CaRS indicated that the gene signatures derived from m.PR and m.CR B-ALL, together with h.CR and h.NR, stratified CD19 CAR T therapy patients with 94% accuracy (Fig. 2E). Here, CD19 is linked to acute lymphoblastic leukemia.